Entresto 50 mg, 100 mg, 200 mg FC tablets
PDF Leaflet Revision Date: 17 November 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Chronic heart failure with reduced or preserved ejection fraction.
Dosage (summary)
Target dose: 200 mg twice daily; start at 100 mg or 50 mg based on prior ACE/ARB use.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- ACE inhibitors
- Aliskiren
- Potassium-sparing diuretics
- Statins
Contraindications
- Sensitivity to sacubitril or valsartan
- Severe renal impairment
- History of angioedema
- Bilateral renal artery stenosis
Common side effects
- Hypotension
- Hyperkalaemia
- Dizziness
- Fatigue
- Cough
Counselling Points
- Monitor blood pressure regularly
- Avoid potassium supplements
- Report any signs of angioedema immediately
Serious warnings
- Risk of angioedema
- Dual blockade of RAAS not recommended
- Monitor renal function
Important Disclaimer
The Entresto 50 mg, 100 mg, 200 mg FC tablets professional information leaflet below is the property of Novartis Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
